RPL23AP63

Across TCGA pan-cancer cohorts, RPL23AP63 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RPL23AP63’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL23AP63 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL23AP63 is over-expressed in tumor, although a few such as UCEC show the opposite, repressed pattern.

KIRC, COAD, and LUAD are the cancer types where RPL23AP63 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL23AP63 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.240	<.001	9	view →
COAD	Female	All	+0.556	<.001	8	view →
LUAD	All	All	+0.271	.001	3	view →
UCEC	All	IV	−0.880	.022	2	view →
LUSC	All	II,III,IV	+0.259	.003	2	view →
THCA	Female	II,III,IV	+0.245	.007	2	view →
HNSC	Male	All	+0.215	.003	2	view →
PRAD	All	All	+0.196	.008	2	view →
KIRP	Male	All	+0.135	.034	2	view →
CHOL	All	All	+0.274	.009	1	view →
LIHC	All	II,III,IV	+0.092	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RPL23AP63–KIRC

Open the KIRC breakdown →